United Therapeutics Announces Buydown of Ralinepag Royalty
Business Wire•04/11/2026•07:00 ET
0
Key Highlights
- ➤United Therapeutics pays $525 million upfront to eliminate Pfizer’s double-digit ralinepag royalty
- ➤Royalty elimination covers all ralinepag formulations, including oral and inhaled versions
- ➤FDA reviews oral ralinepag NDA for pulmonary arterial hypertension, with June 24, 2027 action date
- ➤United Therapeutics continues owing potential $250 million and $150 million milestone payments
- ➤Ralinepag remains investigational and unapproved in every jurisdiction
Expert Statements
James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics
“This transaction demonstrates our confidence in the revenue opportunity for oral ralinepag, which has a pending new drug application under review by the FDA for pulmonary arterial hypertension, as well as the new dry powder inhalation formulation we are developing for a variety of pulmonary indications.”
James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics
“Ralinepag has the potential to bring substantial benefits to large patient populations spanning a number of difficult-to-treat conditions, and we expect it will transform our company in the process.”
The transaction eliminates the double-digit royalty payable to Pfizer on net sales of ralinepag
Royalty elimination applies to all formulations of ralinepag, including both oral and inhaled
Get started
Create a free account to read the full story.